OncoMatch/Clinical Trials/NCT07501156

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Is NCT07501156 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies H3K27M-EIEs for diffuse midline glioma or diffuse intrinsic pontine glioma.

Phase 1/2RecruitingShenzhen Geno-Immune Medical InstituteNCT07501156Data as of May 2026

Treatment: H3K27M-EIEs — The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Intrinsic Pontine Glioma

Glioblastoma

Biomarker criteria

Required: H3-3A K27M

confirmed H3K27M mutation

Prior therapy

Must have received: standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ) (temozolomide)

Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ)

Cannot have received: gliadel implantation

Exception: within 4 weeks before study start

A prior history of gliadel implantation 4 weeks before this study start

Cannot have received: antibody based therapies

Exception: currently receiving

currently receiving antibody based therapies

Lab requirements

Blood counts

absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Peripheral blood absolute lymphocyte count must be above 0.8×10^9/L

Kidney function

creatinine < 1.5×ULN

Liver function

Bilirubin < 1.5×ULN; ALT or AST < 2.5×ULN

Cardiac function

Satisfactory heart functions

Satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN; Peripheral blood absolute lymphocyte count must be above 0.8×10^9/L; Satisfactory heart functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify